Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
K-CAB sales remained strong, and sales of pharmaceuticals for pets also performed steadily. However, business revenue decreased 5.2% year on year. Research and development expenses and other selling, general and administrative expenses increased, resulting in a wider operating loss.
No applicable matters. The notes on the going concern assumption state that there are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥1,455 million (YoY -5.2%) |
| Operating profit | ¥-338 million |
| Ordinary income | ¥-326 million |
| Profit attributable to owners of the parent | ¥-466 million |
| Net income per share | -¥18.10 |
| Equity ratio | End of the current fiscal period 70.6 / End of previous period 65.1 |
| Total assets | ¥11,006 million |
| Net assets | ¥7,830 million |
| Cash flows from operating activities | ¥613,739 thousand |
| Cash flows from investing activities | ¥-292,193 thousand |
| Cash flows from financing activities | ¥1,099,726 thousand |
| Cash and cash equivalents at end of period | ¥4,696,315 thousand |
| Full-year earnings forecast | Net Sales ¥3,980 million / Operating profit ¥165 million (YoY -65.9%) / Ordinary income ¥86 million (YoY -80.4%) / Net income ¥-63 million |
| Revision to Earnings Forecast | Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥86,403 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. The notes on the going concern assumption state that there are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 1 / Company name テムリック株式会社 |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts, and for general investors via live webcast) |
| Issued Shares at Period-End | 26,031,413 |
| Treasury Shares at Period-End | 181 |
| Factors Behind Changes in Business Performance | K-CAB sales remained strong, and sales of pharmaceuticals for pets also performed steadily. However, business revenue decreased 5.2% year on year. Research and development expenses and other selling, general and administrative expenses increased, resulting in a wider operating loss. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it was unable to record milestone revenue or contract upfront payments, which are assumptions underlying the full-year forecast, during the interim period. However, as it expects to recognize these revenues in the second half, it has not changed its full-year forecast. On the cost side, research and development expenses were ¥861 million, up 10.1% year on year, while other selling, general and administrative expenses were ¥592 million, up 6.9%.